Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.

Hdl Handle:
http://hdl.handle.net/10147/620594
Title:
Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
Authors:
McGurgan, Iain J; McGuigan, Christopher
Citation:
Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. 2015, 5 (10):e00396 Brain Behav
Publisher:
Wiley
Journal:
Brain and behavior
Issue Date:
Oct-2015
URI:
http://hdl.handle.net/10147/620594
DOI:
10.1002/brb3.396
PubMed ID:
26516615
Additional Links:
http://onlinelibrary.wiley.com/doi/10.1002/brb3.396/pdf
Abstract:
Increased rates of NMSC (nonmelanoma skin cancer) have recently been reported in people with MG (myasthenia gravis) receiving azathioprine treatment. Guidelines on azathioprine for patients with dermatological and gastrointestinal disorders stress the importance of NMSC risk awareness and prevention. The aim of this study is to assess whether MG patients are being informed of this risk.
Item Type:
Article
Language:
en
Keywords:
SKIN CANCER; MYASTHENIA GRAVIS
MeSH:
Adult; Aged; Aged, 80 and over; Azathioprine; Counseling; Female; Humans; Immunosuppressive Agents; Incidence; Information Dissemination; Male; Middle Aged; Myasthenia Gravis; Patient Medication Knowledge; Risk Factors; Skin Neoplasms; Young Adult
ISSN:
2162-3279

Full metadata record

DC FieldValue Language
dc.contributor.authorMcGurgan, Iain Jen
dc.contributor.authorMcGuigan, Christopheren
dc.date.accessioned2016-09-20T10:40:37Z-
dc.date.available2016-09-20T10:40:37Z-
dc.date.issued2015-10-
dc.identifier.citationNonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients. 2015, 5 (10):e00396 Brain Behaven
dc.identifier.issn2162-3279-
dc.identifier.pmid26516615-
dc.identifier.doi10.1002/brb3.396-
dc.identifier.urihttp://hdl.handle.net/10147/620594-
dc.description.abstractIncreased rates of NMSC (nonmelanoma skin cancer) have recently been reported in people with MG (myasthenia gravis) receiving azathioprine treatment. Guidelines on azathioprine for patients with dermatological and gastrointestinal disorders stress the importance of NMSC risk awareness and prevention. The aim of this study is to assess whether MG patients are being informed of this risk.en
dc.language.isoenen
dc.publisherWileyen
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1002/brb3.396/pdfen
dc.rightsArchived with thanks to Brain and behavioren
dc.subjectSKIN CANCERen
dc.subjectMYASTHENIA GRAVISen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAzathioprine-
dc.subject.meshCounseling-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunosuppressive Agents-
dc.subject.meshIncidence-
dc.subject.meshInformation Dissemination-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMyasthenia Gravis-
dc.subject.meshPatient Medication Knowledge-
dc.subject.meshRisk Factors-
dc.subject.meshSkin Neoplasms-
dc.subject.meshYoung Adult-
dc.titleNonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.en
dc.typeArticleen
dc.identifier.journalBrain and behavioren
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.